Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TBPH

Theravance Biopharma Inc

Apr 18 • 04:00PM ET

9.20

Dollar change -0.32
Percentage change -3.36	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN VB IBB VBK VTWO SCHA VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.97	Insider Own	9.32%	Shs Outstand	48.09M	Perf Week	3.02%
Market Cap	443.07M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	-0.17%	Shs Float	43.68M	Perf Month	3.95%
Income	-55.19M	PEG	-	EPS next Q	-0.25	Inst Own	101.66%	Short Float	17.22%	Perf Quarter	-3.36%
Sales	57.42M	P/S	7.72	EPS this Y	35.20%	Inst Trans	-0.40%	Short Ratio	20.78	Perf Half Y	-1.39%
Book/sh	4.43	P/B	2.08	EPS next Y	38.27%	ROA	-11.16%	Short Interest	7.52M	Perf Year	-21.10%
Cash/sh	2.13	P/C	4.33	EPS next 5Y	-	ROE	-16.86%	52W Range	8.21 - 11.98	Perf YTD	-18.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.22%	ROI	-21.37%	52W High	-23.21%	Beta	0.32
Dividend TTM	-	Quick Ratio	5.39	Sales past 5Y	0.23%	Gross Margin	89.46%	52W Low	12.06%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	5.39	EPS Y/Y TTM	72.89%	Oper. Margin	-92.81%	RSI (14)	49.33	Volatility	5.32% 4.07%
Employees	99	Debt/Eq	0.23	Sales Y/Y TTM	11.84%	Profit Margin	-96.12%	Recom	1.80	Target Price	15.40
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	-11.96%	Payout	-	Rel Volume	1.00	Prev Close	9.52
Sales Surprise	-0.06%	EPS Surprise	-15.25%	Sales Q/Q	19.91%	Earnings	Feb 26 AMC	Avg Volume	361.84K	Price	9.20
SMA20	-0.26%	SMA50	2.57%	SMA200	-4.64%	Trades		Volume	362,260	Change	-3.36%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	BTIG Research	Buy	$21
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform	$12
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral	$12
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight	$7
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight	$27 → $14
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform	$42 → $14
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$32
Jul-07-20	Initiated	JP Morgan	Overweight	$29
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight	$30
May-13-20	Initiated	Cowen	Outperform	$42
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral	$22 → $18
Oct-29-19	Initiated	H.C. Wainwright	Buy	$25
Mar-29-18	Resumed	Piper Jaffray	Overweight	$45
Aug-17-17	Initiated	Evercore ISI	Outperform	$45
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight	$55
May-11-17	Reiterated	Needham	Buy	$40 → $45
Dec-21-16	Initiated	Needham	Buy	$40
Nov-03-16	Initiated	Piper Jaffray	Overweight

Show Previous Ratings

Apr-15-24 07:47AM	Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Apr-10-24 06:00AM	Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 (PR Newswire)
Mar-27-24 11:30AM	Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? (Zacks)
Mar-12-24 03:59PM	Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics (InvestorPlace)
Feb-28-24 10:35AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:47AM	Loading…
Feb-27-24 11:47AM	Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates (Zacks)
Feb-26-24 05:25PM	Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:39PM	Theravance Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-22-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-14-24 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 (PR Newswire)
Jan-12-24 09:35AM	Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround (Zacks)
Jan-05-24 06:00AM	Theravance Biopharma Announces Results from the Phase 4 YUPELRI PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire) -9.98%
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Dec-21-23 05:00PM	Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors (PR Newswire)
06:00AM	Loading…
Dec-18-23 06:00AM	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference (PR Newswire)
Dec-07-23 11:30AM	Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-22-23 09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-16-23 06:00AM	Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System (PR Newswire)
Nov-15-23 06:00AM	Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-13-23 08:00AM	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
Nov-08-23 02:10PM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.34%
11:35AM	Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally (Zacks)
Nov-07-23 06:09PM	Theravance Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:28PM	Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Oct-19-23 06:00AM	Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023 (PR Newswire)
Sep-06-23 11:30AM	Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-31-23 05:55PM	12 High Growth Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Aug-29-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Aug-28-23 06:05AM	Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
06:25AM	Loading…
Aug-09-23 06:25AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 09:54AM	Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss (Zacks)
Aug-07-23 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Theravance Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia)
Jul-24-23 06:00AM	Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 (PR Newswire)
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia)
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
Jun-07-23 11:30AM	Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report? (Zacks)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-11-23 03:41PM	Takeda Moves Out From Licensing Agreement With Theravance Biopharma (Benzinga)
10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 11:34AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Theravance Biopharma First Quarter 2023 Earnings: US$0.35 loss per share (vs US$0.34 loss in 1Q 2022) (Simply Wall St.)
May-09-23 06:00PM	Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy (PR Newswire)
09:24AM	Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates (Zacks)
May-08-23 05:55PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-04-23 10:00AM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-01-23 10:01AM	Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline (Zacks)
Apr-24-23 06:00AM	Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023 (PR Newswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 07:47AM	Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Share Price Not Quite Adding Up (Simply Wall St.)
Apr-14-23 04:23AM	4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-11-23 04:05PM	Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors (PR Newswire)
Apr-10-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Mar-31-23 12:41PM	Top Small-Cap Stocks for April 2023 (Investopedia)
11:30AM	ImmunoGen (IMGN) Down 16.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
11:30AM	Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report? (Zacks)
Mar-29-23 11:30AM	Theravance Bio (TBPH) Down 2% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-10-23 06:56AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 02:50PM	Top Healthcare Stocks for March 2023 (Investopedia)
Mar-02-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-28-23 02:17PM	Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates (Zacks)
01:33PM	Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff (Benzinga)
Feb-27-23 06:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.99%
04:05PM	Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update (PR Newswire)
11:26AM	UPDATE 1-Irenic Capital urges Theravance to conduct review, add shareholder to board (Reuters)
09:00AM	Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review (Business Wire)
Feb-23-23 07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-21-23 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (PR Newswire)
Feb-16-23 10:01AM	Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-15-23 10:00AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-09-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jan-09-23 06:00AM	Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets (PR Newswire) -6.96%
Dec-25-22 09:39AM	Shareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years ago (Simply Wall St.)
Dec-07-22 11:30AM	Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report? (Zacks)
Nov-22-22 04:15PM	Theravance Biopharma, Inc. Announces Final Results of Tender Offer (PR Newswire)
Nov-18-22 06:00AM	Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer (PR Newswire)
Nov-11-22 08:20AM	We Might See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) Soon (Simply Wall St.)
Nov-08-22 08:34AM	Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-07-22 05:45PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer (PR Newswire)
Nov-02-22 04:30PM	Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System (PR Newswire)
Oct-31-22 06:00AM	Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022 (PR Newswire)
Oct-27-22 10:02AM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-26-22 10:02AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 06:00AM	Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System (PR Newswire)
Sep-28-22 06:00AM	Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares (PR Newswire)
Sep-20-22 09:36AM	Company News for Sep 20, 2022 (Zacks)
Sep-19-22 02:28PM	Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings (Benzinga)
07:22AM	UPDATE: Theravance Biopharma plans $250 million capital return program; stock jumps 3% premarket (MarketWatch)
06:00AM	Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program (PR Newswire)
Sep-08-22 11:30AM	Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-06-22 06:00AM	Theravance Biopharma to Present at Upcoming Investor Conferences (PR Newswire)
Aug-14-22 08:06AM	Need To Know: Analysts Are Much More Bullish On Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenues (Simply Wall St.)
Aug-05-22 11:53AM	Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline (Zacks) -7.81%
Aug-04-22 07:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Feb 22 '24	Sale	8.71	1,254	10,922	311,733	Feb 22 08:04 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Nov 21 '23	Sale	10.29	1,378	14,180	331,206	Nov 22 06:07 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Nov 14 '23	Sale	10.22	2,482	25,366	346,839	Nov 16 06:16 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Oct 16 '23	Sale	9.03	2,482	22,412	334,321	Oct 18 06:54 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Sep 14 '23	Sale	9.89	2,482	24,547	336,803	Sep 18 06:08 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Aug 22 '23	Sale	9.47	1,807	17,112	340,566	Aug 24 06:05 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Aug 11 '23	Sale	9.99	2,322	23,197	349,746	Aug 15 06:09 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Jul 14 '23	Sale	9.84	2,322	22,848	352,068	Jul 18 06:14 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Jun 14 '23	Sale	10.69	2,322	24,822	354,390	Jun 16 06:14 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 08 '23	Sale	11.13	1,790	19,923	352,833	Jun 12 06:08 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	May 15 '23	Sale	11.26	2,322	26,146	367,172	May 17 06:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TBPH

Theravance Biopharma Inc

Upgrade your FINVIZ experience